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The news that a new research
institute is to be opened in
Austria is traditionally greeted
with scepticism but the
establishment of the Institute for
Molecular Biotechnology (IMBA)
has given rise to even more
controversy than usual. Part of
the problem is that it was widely
seen to be coupled to the closing
of the Institute of Molecular
Biology (IMB) in Salzburg, to date
one of the flagship institutes of
the Austrian Academy of
Sciences. Another difficulty was
that the future Director of the
IMBA, Josef Penninger, is
relatively young and has not
followed the standard Austrian
career path.
The reasoning behind the
Academy’s decision to close the
IMB reflects its changing view of
the nature of scientific research.
Once the province of talented
individuals, science is gradually
becoming much larger in scope. It
is increasingly the case that the
ability to perform internationally
competitive research, in particular
in more technically oriented fields,
requires a large team of scientists
working closely together. The
Academy felt that the IMB was
simply too small to continue to
function in relative isolation.
Attempts to enlarge it led nowhere
because it proved impossible to
attract financial support to expand
the premises in Salzburg, so the
Academy elected to close the
Institute and make a fresh start
elsewhere. The decision has
understandably led to an uproar in
Austrian scientific circles, not
least because the IMB has been
highly successful in the past and
still houses a number of Austria’s
top groups in the field.
Simultaneously, the Academy
announced the opening of two
new institutes, the IMBA and the
Gregor Mendel Institute for Plant
Molecular Biology (GMI), to be
located in Vienna at the site
already occupied by the Research
Institute of Molecular Pathology
(IMP) and the Vienna Biocentre.
The new institutes can thus
integrate themselves in a group of
facilities that has the necessary
‘critical mass’ to become one of
the key players in molecular
biology and genetics in Europe, if
not in the world. For legal reasons
they are new institutes rather than
a continuation of the IMB but this
gives rise to some problems, for
example they are not able to take
over the (considerable) equipment
presently available at the IMB.
The GMI will place emphasis on
molecular processes and their
regulation in plants. The Institute
will be headed by Dieter
Schweizer, currently Professor at
the Institute of Botany at the
University of Vienna. Other
researchers heading for the GMI
include Marjori and Antonius
Matzke from the IMB in Salzburg
and Heribert Hirt from the Vienna
Biocentre. A number of junior
researchers are also planned to be
recruited.
Whereas the GMI is a ‘typical’
research institute of the Austrian
Academy of Sciences, the IMBA is
being established as a joint
venture between the Academy
and the pharmaceutical company
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Boehringer Ingelheim. The
organisations will be equal
partners: should any potentially
applicable discoveries be made,
for example relating to new
medicines or therapies,
Boehringer will negotiate first for
rights to them.
The partnership represents the
first time in Austria that an
academic organisation and a
privately funded company are
cooperating to support a research
institute. The IMBA also
represents the Academy’s most
tangible effort to make the results
of the basic research it supports
available and applicable to
industry.
The IMBA will share a
considerable amount of
infrastructure with the IMP. A
prime example of this is the
mouse house, which is being
conceived as a central repository
with a capacity of up to 20,000
cages. Additional in-house
facilities to be provided include
microscopy, microarrays, DNA




A high-profile new institute
naturally requires a high-profile
director and the Academy
announced that Josef Penninger
(see accompanying article) will
assume this position. On the face
of it, Penninger meets all the
requirements for the position:
although not yet 40 he has
established a reputation for
innovative research of the highest
international quality (and with the
potential for clinical application)
and as an Austrian he is familiar
with the peculiarities of the
country, providing an insider
knowledge that may prove
invaluable. Nevertheless, he has
come from outside and is thus
viewed with a mixture of suspicion
and envy by many of those within
the country.
Although his existing laboratory
in Toronto will remain in operation
until the end of 2003, Penninger is
already Director of the IMBA and
he plans to move to Vienna in
March, when he and five or six
post-doctoral researchers will
occupy rented space in the
Vienna Biocentre. Work on the
IMBA’s own building is planned to
start in March 2003 and is
scheduled to be completed by the
summer of 2004.
It is planned that the IMBA will
eventually have about 100
scientific workers in ten scientific
groups, of which three (including
Penninger’s own) will be senior
and seven junior. The group
leaders will be selected by a
seven-man search committee
made up of leading scientists: in
addition to Penninger himself and
Peter Schuster (Vice-President of
the Academy), it will comprise
Meinrad Busslinger and Kim
Nasmyth from the neighbouring
IMP, Anton Berns (Netherlands
Cancer Institute, Amsterdam),
Gottfried Schatz (President of the
Swiss Science and Technology
Council, Basel) and Jim Woodgett
(Ontario Cancer Institute,
Toronto). The scientific positions
are currently being advertised
with a closing date for
applications of 15 March 2003.
The level of support provided to
group leaders will be generous
enough to be attractive to
researchers of world standing:
‘senior scientists’ will have seven
post-doctoral positions and junior
scientists three. They will be
offered contracts of five years,
with the possibility of extension
for a further three (as is the case
at the IMP). They will have no
teaching obligations and so will
be free to concentrate on their
research for this period. The
groups will enjoy a high degree of
independence and it is hoped that
the environment will be
stimulating. Finally, there will be
no fixed salary scale for senior
scientists so it will be possible to
offer competitive salaries to
attract top international scientists
to Vienna.
Initial plans for the IMBA were
that it would begin with a focus on
mouse models of human
diseases, addressing the
functions of individual genes in
the origin and progression of
disease. Its aim is to perform
basic research of top quality, with
the hope that this will lead to
applications. More important than
the scientific scope, however, is
the quality of scientists to be
recruited. If leading people apply
to work at the IMBA they will be
hired even if their work does not
fit in with the institute’s main
emphasis. Indeed, the IMBA has
announced that Barry Dickson will
be taking one of the senior
scientist positions. Dickson’s
recent work on the development
of the Drosophila nervous system
has given rise to number of
papers in top-ranking journals.
Although the nervous system of
Drosophila is far less complex
than that of humans, the
molecular mechanisms underlying
aspects of neural development
seem remarkably similar. Dickson
is very much looking forward to
starting. ‘The IMBA is going to be
a great place to work. The
success of the IMP shows what
can be achieved when you get a
group of talented young scientists
together, give them generous
support and a great infrastructure,
and allow them to focus fully on
their research,’ he says.
Although one of its prime aims
is to facilitate the transfer of
knowledge from basic research to
industry, the new institute should
also provide a focus for
interactions between scientists
and society. The IMP holds Open
Days that are well attended —
Penninger hopes that this will also
be the case for the IMBA. But the
IMBA has much more wide-
reaching plans to make contact
with the public. Perhaps more
than other nationalities, Austrians
have a fear of genetics. Penninger
is hoping to help overcome this by
familiarising children with science.
To this end, the IMBA will include
‘public’ laboratories where
primary school children (seven
and eight-year-olds) will be
offered lessons in genetics and
scientific research. The institute
will also collaborate with other
groups in Vienna to run a
laboratory where high-school
teachers will be taught molecular
biology. These activities represent
the first time in Austria that
schoolchildren and teachers are
being specifically addressed on
the issue of biological research.
The IMBA hopes through its
initiative to contribute to a greater
understanding and tolerance of
genetic research in future
generations.
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